The complexity of cancer chemotherapy requires that pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparing, dispensing, and administering antineoplastic therapy and to the agents, commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
KinoshitaA., FukudaM., SodaH.; Nagasaki Thoracic Oncoloy Group (NTOG). Phase II study of irinotecan combined with carboplatin in previously untreated small-cell lung cancer. Br J Cancer.2006; 94(9): 1267–1271.
2.
LaackE., ThömI., KrüllA.A phase II study of irinotecan (CPT-11) and carboplatin in patients with limited disease small cell lung cancer (SCLC). Lung Cancer.2007; 57(2): 181–186.
3.
NakaN., KawaharaM., OkishioK.Phase II study of weekly irinotecan and carboplatin for refractory or relapsed small-cell lung cancer. Lung Cancer.2002; 37(3): 319–323.
4.
HiroseT., HorichiN., OhmoriT.Phase II study of irinotecan and carboplatin in patients with the refractory or relapsed small cell lung cancer. Lung Cancer.2003; 40(3): 333–338.
5.
SchmittelA., Fischer von WeikersthalL., SebastianM.A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer. Ann Oncol.2006; 17(4): 663–667.
6.
SohnJ.H., ChoiH.J., ChangJ.A phase II trial of fractionated irinotecan plus carboplatin for previously untreated extensive-disease small cell lung cancer. Lung Cancer.2006; 54(3): 365–370.
7.
HermesA., BergmanB., BremnesR.Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. J Clin Oncol.2008; 26(26): 4261–4267.
8.
ChenG., HuynhM., FehrenbacherL.Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer. J Clin Oncol.2009; 27(9): 1401–1404.
9.
FukudaM., OkaM., SodaH.; Nagasaki Thoracic Oncology Group. Phase II study of irinotecan combined with carboplatin in previously untreated non-small-cell lung cancer. Cancer Chemother Pharmacol.2004; 54(6): 573–577.
10.
PillotG.A., ReadW.L., HennenfentK.L.A phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: final report. J Thorac Oncol.2006; 1(9): 972–978.
11.
National Comprehensive Cancer Network.NCCN clinical practice guidelines—small cell lung cancer. V.2.2009. http://www.nccn.org. Accessed June 10, 2009.
12.
National Comprehensive Cancer Network.NCCN clinical practice guidelines—non-small cell lung cancer. V.2.2009. http://www.nccn.org. Accessed June 10, 2009.
13.
CheungY.W., CradockJ.C., VishnuvajjalaB.R., FloraK.P.Stability of cisplatin, iproplatin, carboplatin, and tetraplatin in commonly used intravenous solutions. Am J Hosp Pharm.1987; 44(1): 124–130.
14.
HeskethP.J., KrisM.G., GrunbergS.M.Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol.1997; 15(1): 103–109.
15.
National Comprehensive Cancer Network.NCCN clinical practice guidelines—antiemesis. V.3.2008. http://www.nccn.org. Accessed June 11, 2009.
16.
KrisM.G., HeskethP.J., SomerfieldM.R.American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. [published correction appears in J Clin Oncol. 2006; 24(33)5341–5342]. J Clin Oncol.2006; 24(18): 2932–2947.
17.
Multinational Association for Supportive Care in Cancer.Antiemetic guidelines.2008. www.mascc.org. Accessed June 11, 2009.
18.
TerenziL., WaddellJ.Predicting emetogenicity of new cancer chemotherapy agents [abstract]. J Oncol Pharm Pract.2004; 10(2): 84.
19.
TerreyJ.P., AaproM.S.The activity of granisetron in patients who had previously failed ondansetron antiemetic therapy. Eur J Clin Res.1996; 8: 281–288.
20.
CarmichaelJ., KeizerH.J., CupissolD., MilliezJ., ScheidelP., SchindlerA.E.Use of granisetron in patients refractory to previous treatment with antiemetics. Anticancer Drugs.1998; 9(5): 381–385.
21.
de WitR., de BoerA.C., vd LindenG.H., StoterG., SparreboomA., VerweijJ.Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer.2001; 85(8): 1099–1101.
22.
SmithI.E.A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy. The Granisetron Study Group. J Cancer Res Clin Oncol.1993; 119(6): 350–354.
23.
SoukopM.A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Granisetron Study Group. Support Care Cancer.1994; 2(3): 177–183.
24.
GelingO., EichlerH.G.Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol.2005; 23(6): 1289–1294.
ZanottiK.M., MarkhamM.Prevention and management of antineoplastic-induced hypersensitivity reactions. Drug Saf.2001; 24(10): 767–779.
27.
SmithT.J., KhatcheressianJ., LymanG.H.2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol.2006; 24(19): 3187–3205.
28.
National Comprehensive Cancer Network.NCCN clinical practice guidelines in oncology—myeloid growth factors. V.1.2009. http://www.nccn.org. Accessed June 12, 2009.
29.
LarsonD.L.Treatment of tissue extravasation by antitumor agents. Cancer.1982; 49(9): 1796–1799.
30.
LarsonD.L.What is the appropriate management of tissue extravasation by antitumor agents?Plast Reconstr Surg.1985; 75(3): 397–405.
31.
MullinS., BeckwithM.C., TylerL.S.Prevention and management of antineo-plastics extravasation injury. Hosp Pharm.2000; 35(1): 57–74.
32.
BensonAB3rd, AjaniJ.A., CatalanoR.B.Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol.2004; 22(14): 2918–2926.
33.
AronoffG.R., BennettW.M., BernsJ.S.Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children.5th ed.Philadelphia, PA: American College of Physicians; 2007.
34.
KintzelP.E., DorrR.T.Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev.1995; 21(1): 33–64.
35.
FloydJ., MirzaI., SachsB., PerryM.C.Hepatotoxicity of chemotherapy. Semin Oncol.2006; 33(1): 50–67.
